CompuGroup Medical (COP) AI Stock Analysis

• Market Cap: €1.41B
• Dividend Yield: 0.2%
• Average Volume (3M): 3.83K
• Price to Earnings (P/E): 75.7
• Beta (1Y): 0.35
• Revenue Growth: 1.16%
• EPS Growth: -43.53%
• Country: DE
• Employees: 8,299
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 53,734,577
• 10 Day Avg. Volume: 3,449
• 30 Day Avg. Volume: 3,827
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: €28.00 ▲(18.54% Upside)

CompuGroup Medical's overall stock score is driven by stable financial performance and operational efficiency. However, high valuation metrics and technical indicators suggest caution. The lack of earnings call data and corporate events limits additional insights.

Positive Factors

Recurring SaaS and diversified revenue streams

A mixed model of one‑time license sales plus subscription and cloud SaaS creates recurring revenue and higher customer lifetime value. This durability improves predictability, supports retention and upsell, and underpins multi‑year cash flow visibility for reinvestment and debt servicing.

Strong free cash flow and improving operating cash flow

Consistent positive free cash flow and operating cash generation above net income show strong cash conversion. Over months this supports capital expenditure funding, deleveraging, M&A optionality and shareholder returns without relying on equity raises, enhancing financial resilience.

Operational efficiency with solid EBIT/EBITDA margins

Sustained healthy EBIT/EBITDA margins indicate scalable software economics and disciplined cost control. Margin durability allows the company to reinvest in product development and sales, absorb competitive pricing, and convert revenue growth into stable operating profit over multiple quarters.

Negative Factors

Moderate leverage and reliance on debt financing

A moderate debt load reduces financial flexibility and raises sensitivity to interest costs and refinancing cycles. Over a multi‑month horizon this can constrain strategic moves, limit opportunistic M&A, and force prioritization of cash to debt service rather than growth or shareholder distributions.

Relatively low net profit margins

Lower net margins mean operational efficiency isn't fully translating to shareholder returns, leaving less buffer for shocks or investment. Persistently weak net profitability can depress returns on equity and limit retained earnings available for strategic initiatives over the coming quarters.

Limited investor communication and event disclosure

Absence of earnings calls and notable corporate events reduces transparency into strategy execution and management priorities. Over several months this limits investors' ability to assess guidance, hold management accountable, and increases information risk around operational or strategic shifts.

CompuGroup Medical Business Overview & Revenue Model

Company Description

CompuGroup Medical (COP) is a leading global eHealth company that provides software solutions for healthcare providers, including hospitals, practices, and pharmacies. The company operates primarily in the healthcare IT sector, offering a wide range of products and services that facilitate efficient patient management, clinical documentation, electronic health records, and billing processes. CompuGroup Medical aims to enhance the quality and efficiency of healthcare delivery through innovative technology solutions.

How the Company Makes Money

CompuGroup Medical generates revenue through multiple streams, primarily by selling software licenses and providing subscription-based services to healthcare providers. Their core revenue model includes one-time fees for software licenses, ongoing maintenance, and support services. Additionally, the company earns revenue from consulting services, training programs, and cloud-based solutions. Key partnerships with healthcare institutions and governments also contribute to its earnings, as the company often collaborates on projects aimed at improving healthcare delivery systems. Moreover, CompuGroup Medical benefits from a recurring revenue model through its SaaS offerings, which provide a stable income stream as clients pay for ongoing access to their software solutions.

CompuGroup Medical Financial Statement Overview

Summary

CompuGroup Medical demonstrates steady revenue growth and operational efficiency, with solid EBIT and EBITDA margins. However, challenges in net profitability and leverage management remain.

Income Statement

CompuGroup Medical demonstrates steady revenue growth over the years, although recent periods show a slight decline in revenue. The company maintains solid EBIT and EBITDA margins, indicating operational efficiency. However, net profit margins are relatively low, suggesting potential challenges in managing bottom-line profitability.

Balance Sheet

The balance sheet reflects a moderate level of leverage with a debt-to-equity ratio that suggests reliance on debt financing. However, the equity ratio is stable, indicating a satisfactory level of equity financing. The return on equity is modest, pointing to moderate profitability relative to shareholder investment.

Cash Flow

CompuGroup Medical's cash flow statement shows positive free cash flow and an improving trend in operating cash flow, which exceeds net income, suggesting strong cash conversion capabilities. The free cash flow growth rate is positive, although fluctuations in capital expenditures may impact cash flow stability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.16B	1.15B	1.19B	1.13B	1.03B	837.26M
Gross Profit	821.16M	965.14M	1.01B	958.16M	285.89M	712.95M
EBITDA	197.37M	206.90M	215.84M	231.36M	216.63M	192.49M
Net Income	27.00M	34.60M	45.92M	73.41M	68.97M	73.19M
Balance Sheet
Total Assets	2.02B	1.97B	1.90B	1.94B	1.79B	1.57B
Cash, Cash Equivalents and Short-Term Investments	128.64M	107.61M	64.54M	90.96M	107.63M	75.61M
Total Debt	826.65M	879.99M	766.94M	786.47M	741.31M	554.54M
Total Liabilities	1.37B	1.32B	1.23B	1.27B	1.18B	926.84M
Stockholders Equity	651.09M	647.91M	667.68M	672.42M	612.07M	638.67M
Cash Flow
Free Cash Flow	84.57M	65.66M	104.11M	63.99M	87.78M	94.20M
Operating Cash Flow	143.96M	128.88M	179.53M	145.03M	165.27M	149.93M
Investing Cash Flow	-108.83M	-105.28M	-124.33M	-145.41M	-163.98M	-457.12M
Financing Cash Flow	-35.70M	18.81M	-80.69M	-16.36M	30.15M	338.07M

CompuGroup Medical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 23.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:COP, the sentiment is Positive. The current price of 23.62 is below the 20-day moving average (MA) of 26.26, below the 50-day MA of 25.27, and below the 200-day MA of 23.82, indicating a bullish trend. The MACD of 0.46 indicates Positive momentum. The RSI at 57.44 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:COP.

CompuGroup Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M3V	72 Outperform	€44.41M	14.03	24.14%	3.86%	-5.72%	-25.19%
ILM1	70 Outperform	€412.17M	18.01	4.18%	―	9.27%	65.65%
EUZ	64 Neutral	€942.36M	23.70	16.93%	1.11%	9.64%	35.18%
SBS	63 Neutral	€267.43M	16.69	―	2.71%	-1.64%	22.60%
COP	60 Neutral	€1.41B	75.68	2.87%	0.20%	1.16%	-43.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%